MedTrace Logo

Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

NCT00763022 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 302

Last updated 2012-11-12

No results posted yet for this study

Summary

The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in Type 2 Diabetes subjects.

Conditions

Interventions

DRUG

TAK-559

TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.

DRUG

TAK-559

TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.

DRUG

Placebo

TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.

Sponsors & Collaborators

Principal Investigators

  • Sr VP Clinical Science · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2004-12-31
Completion
2004-12-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00763022 on ClinicalTrials.gov